Briacell Therap (NASDAQ:BCTX) Stock Price Up 1.8% – Still a Buy?

Briacell Therap (NASDAQ:BCTX) shares were up 1.8% on Tuesday . The company traded as high as $3.58 and last traded at $3.45. Approximately 61,830 shares were traded during trading, a decline of 41% from the average session volume of 105,626 shares. The stock had previously closed at $3.39.

Analysts Set New Price Targets

BCTX has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research note on Friday, July 17th. Wall Street Zen raised shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Briacell Therap Price Performance

The stock has a market capitalization of $30.02 million, a price-to-earnings ratio of -0.44 and a beta of 1.14. The company’s 50-day simple moving average is $3.34 and its 200-day simple moving average is $3.81.

Briacell Therap (NASDAQ:BCTX) last posted its earnings results on Tuesday, June 9th. The company reported ($0.99) EPS for the quarter.

Institutional Investors Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC purchased a new position in shares of Briacell Therap (NASDAQ:BCTX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned 0.21% of Briacell Therap as of its most recent filing with the Securities and Exchange Commission (SEC). 15.42% of the stock is currently owned by institutional investors and hedge funds.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.